http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013150659-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-23 |
| filingDate | 2013-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013150659-A |
| titleOfInvention | Oral Administration of Calcitonin |
| abstract | 1. A method for oral administration to a human prior to a meal of a pharmaceutical composition comprising calcitonin in combination with one or more oral delivery agents selected from the group consisting of N- (5-chlorosalicyloyl) -8-aminocaprylic acid (5-CNAC), N - (10- [2-hydroxybenzoyl] aminodecanoic acid (SNAD) or N- (8- [2-hydroxybenzoyl] amino) caprylic acid (SNAC) and their disodium salts and hydrates and solvates in which the pharmaceutical composition is administered together with the amount of liquid equal to from about 25 ml to about 100 ml. according to claim 1, in which the pharmaceutical composition is administered in the range from about 10 minutes to about 120 minutes before eating, but not less than 1 hour after the previous meal. 3. The method according to claim 1, in which the liquid is aqueous liquid 4. The method according to claim 1, wherein the amount of liquid is about 50 ml. 5. The method according to claim 1, wherein said pharmaceutical composition comprises: a) an oral delivery agent, which is N- (5-chlorosalicyloyl) ) -8-aminocaprylic acid, N- (10- [2-hydroxybenzoyl] aminodecanoic acid or N- (8- [2-hydroxyb benzoyl] amino) caprylic acid or its disodium salt, hydrate or solvate, and b) from about 0.4 to about 2.5 mg of calcitonin, in which the ratio of the amount of agent for oral delivery, expressed in terms of the corresponding amount of free acid, to the amount calcitonin ranges from about 10 to about 250: 1 in a mass ratio. 6. The method according to claim 5, in which the agent for oral delivery is a disodium salt of N- (5-chlorosalicyloyl) -8-aminocaprylic acid, or a hydrate or solvate of said disodium |
| priorityDate | 2007-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.